CD133 as a Functional Unit in Glioblastoma

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1		Thomas Joyce	--	3257	2023-09-21 22:10:00	\|
2	layout	Jessie Wu	-40 word(s)	3217	2023-09-22 02:55:28	\| \|
3	layout	Jessie Wu	Meta information modification	3217	2023-09-22 02:57:20	\|

This entry is adapted from the peer-reviewed paper 10.3390/curroncol30090601

Biomarkers for resistance in Glioblastoma multiforme (GBM) are lacking, and progress in the clinic has been slow to arrive. CD133 (prominin-1) is a membrane-bound glycoprotein on the surface of cancer stem cells (CSCs) that has been associated with poor prognosis, therapy resistance, and tumor recurrence in GBM. Due to its connection to CSCs, to which tumor resistance and recurrence have been partially attributed in GBM, there is a growing field of research revolving around the potential role of CD133 in each of these processes. However, despite encouraging results in vitro and in vivo, the biological interplay of CD133 with these components is still unclear, causing a lack of clinical application. In parallel, omic data from biospecimens that include CD133 are beginning to emerge, increasing the importance of understanding CD133 for the effective use of these highly dimensional data sets. Given the significant mechanistic overlap, prioritization of the most robust findings is necessary to optimize the transition of CD133 to clinical applications using patient-derived biospecimens.

CD133 stem cell marker glioblastoma chemo/radioresistance recurrence omics

1. Introduction

Glioma is the most common type of primary central nervous system tumor and is characterized by a poor prognosis. Glioblastoma multiforme (GBM) is the most aggressive type of glioma and is defined by its short survival ^[1]. Despite the standard of care consisting of surgical removal followed by chemoradiation therapy, the median survival length of GBM has been found to be only 14.6 months, with a two-year survival rate of 26.5% ^[2]. When only using radiotherapy, however, these values have been found to decrease to 12.1 months and 10.4%, respectively ^[2]. One of the primary reasons for this poor prognosis is the ability of GBM to infiltrate throughout the brain, making complete surgical removal nearly impossible and allowing for resistance and recurrence ^[3].

Increasing evidence has attributed the resistance and recurrence capabilities of GBM to a small population of cells exhibiting stem-like characteristics known as cancer stem cells (CSCs). CSCs are undifferentiated cells that can divide and form two daughter cells: one that retains stem-cell characteristics and one that experiences differentiation, therefore propagating tumor populations ^[4]. Compared to other cancer cells, CSCs can increase tumorigenic potential due to their unlimited proliferation, self-renewal abilities, and resistance tactics, all of which continue to be explored. These traits result in chemo- and radioresistance, allowing for tumor regrowth following conventional therapies ^[5]. As a result, research has focused on identifying CSCs using markers in an attempt to uncover the potential mechanisms behind these processes. CD133 has been one of the most commonly identified and utilized CSC markers, and its existence has been found in various other types of cancer as well, including breast ^[4], lung ^[6], stomach ^[7], prostate ^[8], and ovarian ^[9], amongst others.

CD133, also known as prominin-1, is a membrane-bound glycoprotein on the surface of stem cells. With regard to GBM, it has been affiliated with poor prognosis, therapy resistance, and tumor recurrence ^[4]. However, the majority of recent research has focused mainly on using CD133 to identify CSCs, rather than on how CD133 potentially operates and what pathways it may be involved in to target for optimal treatment approaches. Due to its largely unmatched presence on CSCs and its affiliation with these significant tumor characteristics, however, CD133 in particular has earned enough credibility for its contributions to be explored. As a result, the following is a comprehensive overview of CD133 and its role in glioma, including its possible prognostic correlations, microenvironmental relations, and involvement in therapy resistance and tumor recurrence.

2. CD133 and Glioblastoma Multiforme Prognosis

Despite CD133 being used consistently to identify the presence of CSCs, there is growing research involving its relationship to prognosis and survival rates. Several recent analyses have investigated the correlation between high CD133 expression and overall survival (OS) and progression-free survival (PFS). When conducting these analyses, both Wu et al. (32 studies totaling 1490 patients) and Zhang et al. (10 studies totaling 715 patients) observed an association between high CD133 expression and decreased OS as well as decreased PFS ^[9]^[10]^[11]. Wu et al. also used meta-analyses to specify this correlation, discovering that these results were specific to WHO IV gliomas, but not WHO II-III ^[9]. Han et al. reported similar findings when analyzing the outcomes of 1535 patients across 21 studies, concluding that high CD133 expression was affiliated with poor 2-year OS and PFS. This meta-analysis also discovered that these findings were specific only to high-grade WHO gliomas, specifically III and IV ^[10]. A final meta-analysis, by Abdoli Shadbad et al., also confirmed these findings after investigating 1086 patients across 12 studies and discovering that overexpression of CD133 was correlated with inferior PFS for patients with high-grade gliomas ^[12]. These findings indicate that CD133 expression levels may be correlated with the severity of the diagnosis, which may mean that it can provide prognostic information. However, it is significant to note that there was immense overlap between studies in these meta-analyses, which may have influenced why they produced similar results.

As all of this research has linked the high expression of CD133 with poor prognosis ^[9]^[10]^[11]^[12], Li et al. expanded upon this, discovering a high expression of CD133 particularly when there is a low expression of HOX genes ^[13]. This implied a possible interdependent link between CD133 and HOX genes, suggesting that overexpression of only one of these may be sufficient to perpetuate glioma progression. However, the certification of each of them independently being related to patient survival outcomes also indicated the possibility for combined analyses when exploring glioma prognosis using CD133 ^[13].

It is difficult, however, to attribute these prognoses specifically to CD133 as poor prognosis is incredibly common in GBM. As a result, investigations specifically targeting CD133 can provide insight into its true relationship to prognosis. Studies aimed at this are beginning to emerge, such as a recent study by Chavez-Cortez et al. in which an immunotoxin for CD133 was created from IgY antibodies from birds. Upon applying this immunotoxin both in vitro and in vivo, it was determined that the viability of glioma CSCs was reduced by 55%^[14]. When this was done intratumorally, a 50% reduction in tumor size was also determined. As a result, the targeting of CD133 in particular caused reductions in both tumor size and progression showing that it may be an active factor in OS and PFS ^[14]. Although many more studies are needed in this space, these findings imply a potential direct connection between prognosis and the expression of CD133 cells.

3. CD133 and the Tumor Microenvironment

Recent research has explored the impact that microenvironmental factors have on CD133, suggesting the possibility that changes in the microenvironment may mediate its expression. The exploration of the impact of microenvironmental factors has focused mainly on hypoxia, as rapid tumor proliferation leads to diminished blood supply causing hypoxia and necrosis, as well as driving the stem cell state. As a result, investigating how cells survive in this environment while still allowing GBM in particular to maintain resistance to conventional therapies is crucial for potential treatment approaches. Musah-Eroje and Watson explored this correlation by placing three GBM cell lines in 1% oxygen microenvironments and discovered that there was a significant upregulation of CD133 under hypoxic conditions ^[15] (Figure 1A). Similar research has confirmed this increased expression due to hypoxia in the microenvironment ^[16]^[17]^[18], with Ahmed et al. confirming this in both 2D and 3D models ^[19].

Figure 1. CD133 (PROM1) interaction network limiting interaction to molecules in cancer based on the IPA molecule activity prediction ((QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis) accessed on 24 July 2023)^[20]. Network comparison analysis with (A) Activation of HIF1A (e.g., under hypoxia conditions) results in increased predicted expression of PROM1 and the hypothesis is that this drives tumor recurrence. (B) Inhibition of STAT3 results in decreased predicted expression of PROM1 and the hypothesis is that this can lead to tumor response. The same downstream mediators appear to be involved, given current evidence, with PROM1 activation or inhibition driving activation/inhibition of downstream molecules.

However, these discoveries are not solely focused on the impact of hypoxia, but instead on the possible inferences that can be made utilizing these observed effects. Musah-Eroje and Watson also discovered the reversibility of CD133 expression, suggesting that there may be a more significant linkage between CD133 expression and the microenvironment ^[15]. Their findings imply that gene expression is based on the microenvironment and that GBM cells are adaptive to this environment, changing expression qualities in a dynamic manner. Therefore, this may provide insight into the movement of GBM cells as well as treatment mechanisms revolving around the genetic characteristics that control these changes in expression ^[15]. Brown et al. observed a similar change in phenotype based on microenvironmental conditions, witnessing the ability of CD133+ cells to transform into CD44+ cells. This ability was possibly linked to CD133+ cells actively cycling, allowing for this manipulation of phenotype ^[16].

In contrast, Lee et al. suggested that CD133 expression has the ability to modify the microenvironment rather than the reverse. This research explored the relationship between CD133 and the IL-1β signaling pathway and the downstream chemokines associated with it ^[17]. Although this research did not present findings that this activation led to increased survival or proliferation, they did find an influx of neutrophils into the tumor microenvironment. Therefore, Lee et al. concluded that CD133-expressing glioma cells may be able to modify the tumor microenvironment by recruiting neutrophils and inflammatory cells to produce GBM resistance ^[17]. As a result, the relationship between CD133 expression and the microenvironment has been established, but the directionality of this relationship is still in contention.

4. CD133 and Resistance

The majority of the current research field has explored the correlation between CD133+ glioma cells and chemo- and radioresistance, however, there is a growing field that is investigating the contributions of CD133 as a functional unit in this resistance. Because of this, there is a currently increasing consensus regarding the involvement of CD133 in tumor resistance, but the mechanism by which this occurs is unclear with various possibilities.

In regard to chemotherapy, there is still debate as to whether CD133 is involved in the resistance of glioma cells to temozolomide (TMZ), a common oral chemotherapeutic ^[21]. Although some research has discovered higher TMZ resistance with the presence of CD133 ^[19], the majority of more recent studies have not identified indications of its role in TMZ resistance when downregulating CD133 ^[18]^[21]^[22]. Despite this, Miao et al. investigated the role of CD133 in apoptosis specifically when treated with TMZ. It was discovered that following TMZ treatment, the apoptotic rate of CD133+/-U251R cells was much lower ^[23]. Along with this, the expression of the p53 upregulated modulator of apoptosis (PUMA), a crucial product of antitumor drugs that promotes apoptosis, was especially low in CD133+U251R cells, suggesting the possible downregulation of PUMA by CD133-expressing cells. As a result, the findings showed that the reintroduction of PUMA led to increased apoptotic rates, implying that the dual usage of PUMA and TMZ may be effective as a treatment approach ^[23].

Shifting to cisplatin, another chemotherapeutic, Ahmed et al. recently reported a possible direct involvement of CD133 in the resistance of GBM by also looking at apoptosis. The downregulation of CD133 resulted in an increase in cisplatin effectiveness ranging from two-fold, all the way to seven-fold in U251 cells. This was attributed to the connection between CD133 and the phosphoinositide 3-kinase (PI3K) 85 kDa regulatory subunit, which initiates the PI3K/protein kinase B (Akt) pathway. This Akt pathway is an anti-apoptotic pathway, suggesting the direct involvement of CD133 in this resistance as a crucial and functional unit ^[19]. Also, cisplatin resistance of HIF mechanisms was displayed which also seemed to be dependent on CD133, indicating yet another way in which it may be involved in resistance ^[19]. To showcase the potential effects of the increased expression of CD133 (PROM1), its downstream effects were illustrated in IPA and it was observed that its increased expression predicted the coinciding increased expression of several of these downstream mediators (Figure 1A) ^[20].

Juric et al. also explored the effects of CD133 on apoptosis by investigating the connection between CD133 and cyclin-dependent kinases (CDKs). By using CDK inhibitors, it was found that sphere size was decreased and apoptosis increased when incorporated. As a result, this led to the potential explanation that CDK reduction would mean the presence of less anti-apoptotic agents, namely Mcl-1. This reveals yet another pathway that could be targeted when assessing effective new treatment techniques ^[22].

Rather than preventing apoptosis, Song et al. instead investigated the possible involvement of CD133 in the repair functions of GBM cells. This analysis confirmed that CD133+CSCs were associated with drug resistance, but a further inquiry into this mechanism revealed the communicative relationship between CD133 and Sox2, a neural stem cell marker ^[24]. It was determined that the removal of Sox2 decreased tumor cell population survival and sphere formation, seemingly indicating its involvement in drug resistance ^[24]. Due to the discovery of this interconnection, this is yet another avenue that can be explored.

Sun et al. focused more specifically on the role of CD133 in autophagy brought upon by nutrient-sparse microenvironments. Upon the discovery that cells expressing CD133 had an increased ability to survive, a connection between CD133 and mTOR was determined in which the two appeared to have a coinciding influence on autophagy ^[18]. From these findings and others in this research field, it was inferred that CD133 plays a potential role in creating phagophores in its fusion process as well as through the presence of CD133-containing particles in its composition. There also seems to be a potential role of CD133 in lysosome degradation processes ^[18]. Combined, both of these help to explain how CD133 contributes to the resistance of GBM, allowing for survival in difficult environments.

Although these all appear to be very different approaches to the involvement of CD133 in the resistance of GBM, what they display is the growing field focused on CD133 itself. This research presents the trend in the data to explore the mechanisms by which CD133 is involved in resistance and, by elucidating these, provide potential treatment approaches. More research is needed in this realm to provide more clarity as to which of these avenues is most promising, however through this presentation, it is possible to see that apoptosis prevention, repair, and autophagy involvement are all emerging areas of focus.

5. CD133 and Recurrence

As with the research field focused on resistance, recurrence has become another growing area of interest due to its affiliation with CD133+ cells. Across studies, it has been identified that recurrent GBM has higher expressions of CD133 when compared to the initial tumors ^[25]. This is significant because it shows that there are more CSCs in the recurrent tumor, possibly due to the contribution of CD133. Additionally, a recent meta-analysis found that the time to distant recurrence was decreased by the overexpression of CD133, implying its contribution ^[12]. However, the role of CD133 in this recurrence has only recently begun to be explored.

Defining the importance of CD133 with respect to recurrence was first necessary, and Chang et al. explored the exact tumorigenic changes that occurred when CD133 was present and removed. It was determined that when present, CSCs were able to form neurospheres, and these neurospheres contained markers for neural, embryonic, and pluripotent stem cells ^[26]. Additionally, when placed in nude mice, only the CD133+ population was able to grow tumors in vivo, as the CD133- population could not. It was also discovered that STAT3 was present at a higher rate in CD133+ cells and that when inhibited, the ability of these cells to form neurospheres was decreased. This showed that the inhibition of STAT3 may be a promising route for reducing the effectiveness of CD133 in tumorigenesis^[26]. In fact, to showcase the potential effect of the decreased expression of STAT3 the immediate interactions of CD133 were illustrated in IPA and a decreased expression of PROM1 was observed which also acted to inhibit several downstream mediators (Figure 1B) ^[20].

Sun et al. conducted one of the few studies that have aimed to expose the possible mechanistic involvement of CD133 in recurrence. The focus of this research was on the promoter regions of CD133, of which there are five shown in Figure 2, accompanied by the downstream effects of CD133 on the Akt pathways. Only three promoters (P1–P3) are on the CpG island, however, where they are exposed to methylation. It was determined that the hypomethylation of P2 specifically was required for CD133 transcription^[27]. Additionally, when a demethylating agent was introduced, this increased the presence of CD133 mRNA. As a result, if this progression is to be proven and the functional operations of CD133 solidified, this is a crucial insight into controlling its presence ^[27]. A study by Zhao et al. took a similar approach, finding that the insertion of the HMGB1 gene in CD133-expressing cells limited the multiplication of these cells while also inducing apoptosis ^[28]. As a result, the inhibition of this gene may be a component of how CD133 contributes to tumorigenesis.

Figure 2. Alternative promoters (tissue specific) and the downstream effects of CD133 activation on the Akt pathway with implications for pluripotency, tumorigenesis, cell cycle effects, apoptosis and cell survival, protein synthesis, and angiogenesis based on IPA molecule activity prediction ((QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis) accessed on 24 July 2023) ^[20].

Wei et al. also looked comprehensively at the mechanism that may be causing recurrence. It was determined that the N-glycan increased the interaction between CD133 and DNMT1, and research has suggested that the progression moves from CD133 to DNMT1 ^[29]. This interaction then increased p21 and p27, which contributed to CSC quiescence: when cells are nonproliferating and frozen in the G0 state for survival. Further research is needed, however, to determine how this interaction moves CSCs from the quiescence to the proliferating state. From this, however, Wei et al. was able to conclude that CD133 has an essential role in quiescence, recurrence, and tumorigenesis. Along with this, the inhibition of the CD133–DNMT1 interaction made CSCs more vulnerable to TMZ treatment ^[29].

Similar to resistance, how CD133 specifically contributes to recurrence is still debated as the current research field seeks to propose and confirm its mechanistic involvements. However, it has been made increasingly clear that its presence is central to the reformation of GBM tumors through neurosphere formation. These various pathway connections also imply that CD133 plays a significant role in this process, and that, once elucidated, could be an integral target when creating treatment approaches.

6. Conclusion

Although there is still a lack of consensus regarding the exact mechanistic relationships of CD133 to prognosis, the tumor microenvironment, resistance, and recurrence, these fields of research are rapidly progressing. The role of CD133 as a functional unit involved in each of these continues to gain momentum. A comprehensive understanding of the role of CD133 remains elusive but is crucial as omic data becomes increasingly accessible, since CD133 will be included in panels aimed at measuring and classifying tumor resistance. As a result, being aware of its functions and the meaning of its alteration will become incredibly significant due to its potential ability to track prognosis, as well as its possible role as a treatment target. Clarity into which of these mechanisms is most significant creates immense potential for the utilization of CD133 to develop treatment mechanisms, as its inhibition may reduce the tumorigenic and resistance capabilities of GBM. In conclusion, further advancement regarding the role and linkage of CD133 could allow for additional prognostic and predictive uses as well as specific pathways that can be exploited in treatment approaches and mechanisms in the future.

References

Song Nie; Mikel Gurrea; Jianhui Zhu; Smathorn Thakolwiboon; Jason A. Heth; Karin M. Muraszko; Xing Fan; David M. Lubman; Tenascin-C: A Novel Candidate Marker for Cancer Stem Cells in Glioblastoma Identified by Tissue Microarrays. J. Proteome Res. 2014, 14, 814-822.
Roger Stupp; Warren P. Mason; Martin J. van Den Bent; Michael Weller; Barbara Fisher; Martin J.B. Taphoorn; Karl Belanger; Alba A. Brandes; Christine Marosi; Ulrich Bogdahn; et al.Jürgen CurschmannRobert C. JanzerSamuel K. LudwinThierry GorliaAnouk AllgeierDenis LacombeJ. Gregory CairncrossElizabeth EisenhauerRené O. Mirimanoff Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New Engl. J. Med. 2005, 352, 987-996.
Ting Sun; Guilin Chen; Yanyan Li; Xueshun Xie; Youxin Zhou; Ziwei DU; Aggressive invasion is observed in CD133−/A2B5+ glioma-initiating cells. Oncol. Lett. 2015, 10, 3399-3406.
Khalilullah Mia-Jan; So Young Jung; Ik-Yong Kim; Sung Soo Oh; EunHee Choi; Sei Jin Chang; Tae Young Kang; Mee-Yon Cho; CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy. BMC Cancer 2013, 13, 166-166.
Gina Lee; Brenda Auffinger; Donna Guo; Tanwir Hasan; Marc Deheeger; Alex L. Tobias; Jeong Yeon Kim; Fatemeh Atashi; Lingjiao Zhang; Maciej S. Lesniak; et al.C. David JamesAtique U. Ahmed Dedifferentiation of Glioma Cells to Glioma Stem-like Cells By Therapeutic Stress-induced HIF Signaling in the Recurrent GBM Model. Mol. Cancer Ther. 2016, 15, 3064-3076.
Alexei V. Salnikov; Jury Gladkich; Gerhard Moldenhauer; Manfred Volm; Ingrid Herr; Jürgen Mattern; CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int. J. Cancer 2009, 126, 950-958.
Yu, J.W.; Zhang, P.; Wu, J.G.; Wu, S.H.; Li, X.Q.; Wang, S.T.; Lu, R.Q.; Ni, X.C.; Jiang, B.J. Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma. J. Exp. Clin. Cancer Res. 2010, 29, 141.
Ewa Missol-Kolka; Jana Karbanová; Peggy Janich; Michael Haase; Christine A. Fargeas; Wieland B. Huttner; Denis Corbeil; Prominin-1 (CD133) is not restricted to stem cells located in the basal compartment of murine and human prostate. Prostate 2010, 71, 254-267.
Bin Wu; Caixing Sun; Fang Feng; Minghua Ge; Liang Xia; Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis. J. Exp. Clin. Cancer Res. 2015, 34, 1-12.
Han, M.; Guo, L.; Zhang, Y.; Huang, B.; Chen, A.; Chen, W.; Liu, X.; Sun, S.; Wang, K.; Liu, A; et al. Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis. Mol. Neurobiol. 2016, 53, 720-727.
Wei Zhang; Huanran Chen; Shengqing Lv; Hui Yang; High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma. Mol. Neurobiol. 2015, 53, 2354-2360.
Mahdi Abdoli Shadbad; Negar Hosseinkhani; Zahra Asadzadeh; Oronzo Brunetti; Nicola Silvestris; Behzad Baradaran; The Prognostic Value of CD133 in Predicting the Relapse and Recurrence Pattern of High-Grade Gliomas on MRI: A Meta-Analysis. Front. Oncol. 2021, 11, 722833.
Li, B.; McCrudden, C.M.; Yuen, H.F.; Xi, X.; Lyu, P.; Chan, K.W.; Zhang, S.D.; Kwok, H.F. CD133 in brain tumor: The prognostic factor. Oncotarget 2017, 8, 11144-11159.
Elda-Georgina Chavez-Cortez; Gustavo Vargas Felix; Edgar Rangel López; Julio Sotelo; Carlos Martínez-Canseco; Verónica Pérez-De la Cruz; Benjamin Pineda; Production and Evaluation of an Avian IgY Immunotoxin against CD133+ for Treatment of Carcinogenic Stem Cells in Malignant Glioma: IgY Immunotoxin for the Treatment of Glioblastoma. J. Oncol. 2019, 2019, 1-15.
Ahmed Musah-Eroje; Sue Watson; Adaptive Changes of Glioblastoma Cells Following Exposure to Hypoxic (1% Oxygen) Tumour Microenvironment. Int. J. Mol. Sci. 2019, 20, 2091.
Daniel V. Brown; Gulay Filiz; Paul M. Daniel; Frédéric Hollande; Sebastian Dworkin; Stephanie Amiridis; Nicole Kountouri; Wayne Ng; Andrew P. Morokoff; Theo Mantamadiotis; et al. Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity. PLOS ONE 2017, 12, e0172791.
Lee, S.Y.; Kim, J.K.; Jeon, H.Y.; Ham, S.W.; Kim, H. CD133 Regulates IL-1β Signaling and Neutrophil Recruitment in Glioblastoma. Mol. Cells 2017, 40, 515-522.
Sun, H.; Zhang, M.; Cheng, K.; Li, P.; Han, S.; Li, R.; Su, M.; Zeng, W.; Liu, J.; Guo, J.; et al. Resistance of glioma cells to nutrient-deprived microenvironment can be enhanced by CD133-mediated autophagy. Oncotarget 2016, 7, 76238-76249.
Ahmed, E.M.; Bandopadhyay, G.; Coyle, B.; Grabowska, A. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells. Cell. Oncol. 2018, 41, 319-328.
Andreas Krämer; Jeff Green; Jack Pollard; Stuart Tugendreich; Causal analysis approaches in Ingenuity Pathway Analysis. Bioinform. 2013, 30, 523-530.
Perazzoli, G.; Prados, J.; Ortiz, R.; Caba, O.; Cabeza, L.; Berdasco, M.; Gonzalez, B.; Melguizo, C. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS ONE 2015, 10, e0140131.
Viktorija Juric; Heiko Düssmann; Martine L. M. Lamfers; Jochen H. M. Prehn; Markus Rehm; Brona M. Murphy; Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM. Cells 2021, 10, 1182.
Wang Miao; Xiaodong Liu; Hongqin Wang; Yimin Fan; Shizhong Lian; Xin Yang; Xinxing Wang; Geng Guo; Qichao Li; Sifei Wang; et al. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis. Mol. Med. Rep. 2015, 11, 4165-4173.
Wen-Shin Song; Yi-Ping Yang; Chi-Shuan Huang; Kai-Hsi Lu; Wei-Hsiu Liu; Wai-Wah Wu; Yi-Yen Lee; Wen-Liang Lo; Shou-Dong Lee; Yi-Wei Chen; et al.Pin-I HuangMing-Teh Chen Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells. J. Chin. Med Assoc. 2016, 79, 538-545.
Bülent Polat; Gisela Wohlleben; Rebekka Kosmala; Dominik Lisowski; Frederick Mantel; Victor Lewitzki; Mario Löhr; Robert Blum; Petra Herud; Michael Flentje; et al.Camelia-Maria Monoranu Differences in stem cell marker and osteopontin expression in primary and recurrent glioblastoma. Cancer Cell Int. 2022, 22, 1-11.
Chia-Hsin Chang; Wei-Ting Liu; Hui-Chi Hung; Chia-Yu Gean; Hong-Ming Tsai; Chun-Lin Su; Po-Wu Gean; Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells. BMC Cancer 2017, 17, 1-10.
Sun, B.; Wan, Z.; Shen, J.; Ni, L.; Chen, J.; Cui, M.; Ni, H.; Shi, W.; Shi, J. DNA hypomethylation of CD133 promoter is associated with recurrent glioma. Oncol. Rep. 2016, 36, 1062-1068.
W. P. Zhao; Q. X. Chen; Effects of HMGB1 on proliferation and apoptosis of human brain glioma CD133 cells. Bratisl. Med J. 2015, 116, 480-485.
Sandra Bien-Möller; Ellen Balz; Susann Herzog; Laura Plantera; Silke Vogelgesang; Kerstin Weitmann; Carolin Seifert; Matthias A. Fink; Sascha Marx; Angela Bialke; et al.Chitra VenugopalSheila K. SinghWolfgang HoffmannBernhard H. RauchHenry W. S. Schroeder Association of Glioblastoma Multiforme Stem Cell Characteristics, Differentiation, and Microglia Marker Genes with Patient Survival. Stem Cells Int. 2018, 2018, 1-19.

© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Oncology

Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

Thomas Joyce

Sarisha Jagasia

Erdal Tasci

Kevin Camphausen

Andra Valentina Krauze

View Times: 228

Update Date: 22 Sep 2023

Table of Contents

Video Upload Options

Confirm